Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "USFDA inspection concludes at Zydus' manufacturing plant at Moraiya, Ahmedabad".
Filed with NSE · ISIN INE010B01027 · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding the conclusion of a USFDA inspection at its manufacturing plant in Moraiya, Ahmedabad. The inspection took place over several days and resulted in five observations that the company will address with the USFDA. This filing serves as a disclosure in accordance with regulatory requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Story so far
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 05, 2026, titled "Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.".
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 13, 2026, titled "Zydus and Formycon: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by USFDA".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 12, 2026, titled "Zydus Therapeutics Presents New Post Hoc Analysis of Phase 3 EPICS-III Trial at ACG 2026 Showing Greater Biochemical Response With Investigational Saroglitazar Compared to Placebo Across Geographic Subgroups in PBC".
- Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.
- Zydus Lifesciences Limited Press Release Sep 26 2026
- Zydus Lifesciences Limited Press Release Aug 31 2026
Later from Zydus Lifesciences
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Zydus Sunshine Lifesciences signs agreement with Board of Investment, Sri Lanka to establish a pharmaceutical manufacturing facility in Sri Lanka".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity".
- Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Zylidac Bio and Prolific Machines Partner to Scale Prolific s Next-Generation Biologics Manufacturing Platform to GMP Production".
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences